<DOC>
	<DOCNO>NCT00191503</DOCNO>
	<brief_summary>There standard treatment patient population ask participate study . Although one current regimen , use investigator , high rate response compare therapy , associate moderate severe toxicity . As gemcitabine pemetrexed broad range activity cancer reasonable determine active safe patient type cancer.The objective study determine anti-tumor activity pemetrexed gemcitabine patient condition .</brief_summary>
	<brief_title>Gemcitabine Pemetrexed Primary Unknown Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically proven adenocarcinoma No obvious primary routine history , physical examination , investigation Patients great equal 18 year age ECOG Performance Status 01 Patients require opioids pain control must fix analgesic regimen aim provide adequate pain control 3 breakthrough ( supplemental ) dose analgesic per day control pain ; Additional inclusion criterion due apply , list . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry Unable stabilize pain analgesic period 7 day prior start study treatment Prior treatment chemotherapy Bilirubin great equal 40 mol/L AST ALT great equal 5 time upper limit normal ( ULN ) ; Additional exclusion criterion due apply , list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>